Imbio, a leading medical imaging artificial intelligence (AI) provider for chronic lung and cardiothoracic diseases, and Riverain Technologies, a leader in clinical AI for lung nodules, have announced a collaboration to provide clinicians, health systems, and radiology facilities with a more comprehensive lung health solution through a joint offering of their FDA cleared AI tools.
Riverain and Imbio also have scientifically proven thoracic imaging products that use machine learning and deep learning to assist clinicians in diagnosing lung diseases using digital data-driven tools.
Imbio is the first company that can provide fully automated quantitative analysis and 3D visualization of lung diseases like COPD, emphysema, and Interstitial Lung Diseases. The company's patented Functional Lung Density Analysis (LDAf) algorithm helps to visualize the components of COPD by providing a complete mapping of normal lung, air-trapping, and regions of chronic low density in a combined image, while their Lung Density Analysis Inspiration (LDAi) algorithm aids in the quantification and visualization of emphysema in low dose CT scans.LDAi also produces personalized reports for face-to-face patient communication, which can be used to educate people about their lung problems and help them quit smoking.
ClearRead solutions from Riverain Technologies include intelligent, enterprise-wide, standard-of-care AI tools for the early and effective diagnosis of lung nodules. Using patented suppression technology in thoracic CT and X-ray images, their ClearRead suite greatly enhances a clinician's ability to reliably and effectively diagnose disease – for earlier, more efficient detection of lung abnormalities.
About Riverain Technologies
Riverain is committed to detecting lung disease as soon as possible. The opportunities for machine learning and software solutions in healthcare, according to Riverain, are at an all-time high. Never before has there been such a great opportunity to 'do more for less.' They believe that tools with increasing levels of intelligence can make decision-making easier, resulting in better patient outcomes.
Imbio is a leader in fully automatic AI image analysis for pulmonary and cardiothoracic conditions, both acute and chronic. Imbio's technologies improve physician productivity and patient care by transforming how patients are discovered, diagnosed, and treated. Imbio's solutions are completely automated, have received regulatory approval, and are available through their global partners.